|
|
Volumn 22, Issue 13, 2004, Pages 2519-2521
|
|
The use and development of germline polymorphisms in clinical oncology
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DNA;
DRUG METABOLIZING ENZYME;
GLUCURONOSYLTRANSFERASE 1A1;
MESSENGER RNA;
TATA BINDING PROTEIN;
THYMIDYLATE SYNTHASE;
DNA BINDING PROTEIN;
ERCC2 PROTEIN, HUMAN;
HELICASE;
PROTEIN;
TRANSCRIPTION FACTOR;
X RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;
X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;
XERODERMA PIGMENTOSUM GROUP D PROTEIN;
DNA POLYMORPHISM;
EDITORIAL;
GENE;
GENE SEQUENCE;
GENETIC SCREENING;
GENETIC TRANSCRIPTION;
GENETIC VARIABILITY;
GERM LINE;
HETEROZYGOSITY;
ONCOLOGY;
PHARMACOGENETICS;
PRIORITY JOURNAL;
PROTEIN FUNCTION;
RNA STABILITY;
RNA TRANSLATION;
TANDEM REPEAT;
XPD GENE;
XRCC 1 GENE;
GENETIC POLYMORPHISM;
GENETICS;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
MUTATION;
NOTE;
PATHOLOGY;
PROGNOSIS;
CARCINOMA, NON-SMALL-CELL LUNG;
DNA HELICASES;
DNA, NEOPLASM;
DNA-BINDING PROTEINS;
GERM-LINE MUTATION;
HUMANS;
LUNG NEOPLASMS;
MEDICAL ONCOLOGY;
POLYMORPHISM, GENETIC;
PROGNOSIS;
PROTEINS;
TRANSCRIPTION FACTORS;
XERODERMA PIGMENTOSUM GROUP D PROTEIN;
|
|
EID: 4344619012
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2004.04.900 Document Type: Editorial |
|
Times cited : (25)
|
|
References (9)
|
